Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — FY2019 Earnings Presentation
19 slides from Lincoln Pharmaceuticals's earnings presentation, 2019
Slide 1: Q4 and Full Year FY2019 Earnings Presentation
Q4 and Full Year FY2019 Earnings Presentation Providing Affordable and Innovative medicines for healthier lives
Slide 2: Highlights
Highlights FY2019 vs. FY2018 Management Perspective “Continuing on the strong growth momentum we gained during last year, we o Total Income of Rs. 3,718 million, up 1.3% have reported an robust financial performance during the year primarily on account of increasing export sales and restored demand
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q4 y-o-y Q3 q-o-q Full Year y-o-y Particulars FY2019 FY2018 Growth (%) FY2019 Growth (%) FY2019 FY2018 Growth (%) Total Income 784.5 679.7 15.4% 848.1 (7.5)% 3,718.3 3,670.9 1.3% EBITDA 103.1 105.1 (1.8)% 139.9 (26.3)% 728.3 577.7 26.1% Margin
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 17.7% 4% 2% 3% 2% General Anti Infectives 21.2% 9% 24% 28.4% 25.1% Respiratory Systems Therapeutic Area 0.4% 2.7% 14% Alimentary Tract and Metabolism 1.5% Genito Urinary System and Sex Hormones FY19 9.4% 13% FY18 15% Musculo-Skeletal System 0.2% 8.9% 14% Parasito
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) 15.5% 2.2% 15.4% (33.0)% (43.8)% 679.7 1,021.2 1,070.4 848.1 784.5 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 EBITDA (Rs. million) and Margin (%) 25.1% 22.0% 15.4% 16.5% 13.1% 105.1 255.9 235.2 139.9 103.1 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19
Slide 6: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 0.46x 0.97x 0.87x 0.68x 0.29x 0.26x 0.54x 0.47x 0.18x 0.18x Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 ROCE1 RONW2 24.3% 22.1% 21.6% 19.0% 19.6% 19.2% 17.9% 18.1% 15.8% 15.4% Q4 FY18 Q1 FY19 Q2 FY19 Q
Slide 7: Leverage Profile
Leverage Profile (Rs. million) Mar 2019 Mar 2018 Credit Rating Long Term Debt 53.6 105.7 o CRISIL Short Term Debt 733.7 919.6 Long term bank facilities: A-/Stable Total Debt 787.3 1,025.3 Short term bank facilities: A2+ o ICRA Less: Cash & Cash Equivalents 75.8 145.9 Long term bank facilities:
Slide 8: Recent Developments
Recent Developments 1 Becomes the producer of renewable power energy for captive consumption • In addition to two windmills, the Company has also set up a new Solar Plant of 1 MW at factory’s rooftop with a capacity of producing 15 Lakh Power Unit PA 2 Setting up API production unit • Applied to Pol
Slide 9: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 4.0% 3.2% 2.4% 2.0% 2.7% 148.1 Senior Scientist 15 117.3 Junior Scientist 18 1.6% 88.5 Analysts 18 79.5 72.6 Regulatory Personnel 12 Administrative Personnel 9 34.3 Others 6 Total 78 FY14 FY15 FY16 FY17 FY18 FY19 9
Slide 10: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 4 Patents granted 1,700 Registered products 60+ 25 25 Patents applications 700 in pipeline Countries States across India 300+ 72nd 15+ Formulations developed Rank in AIOCD Therapeutic areas 650
Slide 11: Key Milestones
Key Milestones Received WHO – Becomes Public Covered 80% Installed Windmill Developed & Launch 3 products which are Targeting Many New GMP for plant / Limited Company of all India 600 KVA launched 2 more first time in India. Entered in Countries in West Africa & production unit from a Partnership Ma
Slide 12: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 25 States across India Jammu Uttaranchal Chandigarh Delhi Europe: Ambala Ghaziabad France Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada C
Slide 13: Best-in-Class Facilities
Best-in-Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Cap
Slide 14: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-diuretics/ Anti-malarial Anti-viral/ Anti-
Slide 15: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride α-β Arteether Injection Artesunate for Injection 60 mg Anti Cold Capsules 150
Slide 16: Key Developments
Key Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better patient com
Slide 17: Key Developments
Key Developments o Domi Up Spray • Meter dose pump • Each squirt (spray) accurately delivers 2 mg Ondansetron Hydrochloride • Faster onset of action • Prompt relief from nausea & vomiting • Convenient for patient over Injectable • Better patients compliance o Namcold DX • First time in India: ‘Exten
Slide 18: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 19: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 062. Gujarat, INDIA. Phone :+91-79-67778000 • Fax:+91-79-67778062 E-mail:info@lincolnpharma.com www.lincolnpharma.co.in KP Sompura, Finance Head sompurakp@lincolnpharma.com Lincoln Pharmaceuticals +91 79 677
Lincoln Pharmaceuticals — FY2019 Earnings Presentation on 6ix